APOL3 Orchestrates Metastasis and Enzalutamide Resistance via STAT3-DAB2IP Signaling in Prostate Cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Advanced prostate cancer (PCa) faces challenges with metastatic spread and enzalutamide resistance.
• The role of apolipoprotein L3 (APOL3) in PCa progression and resistance, particularly its interaction with the STAT3-DAB2IP axis, is not well understood.

Purpose of the Study:

• To investigate the mechanistic role of APOL3 in prostate cancer (PCa) progression and enzalutamide resistance.
• To explore the regulation of the STAT3-DAB2IP axis by APOL3 in PCa.
• To evaluate APOL3 as a therapeutic target for overcoming enzalutamide resistance.

Main Methods:

• Analysis of public clinical datasets for APOL3 expression and prognostic value.
• In vitro and in vivo studies using PCa models to assess the effects of modulating APOL3 and DAB2IP.
• RNA sequencing, co-immunoprecipitation (Co-IP), and phenotypic assays to elucidate mechanisms.

Main Results:

• APOL3 is upregulated in PCa, correlating with poor prognosis, and promotes proliferation, metastasis, and angiogenesis.
• APOL3 sustains STAT3 phosphorylation, suppresses DAB2IP, and directly interacts with DAB2IP.
• APOL3 induces enzalutamide resistance by binding the Glucocorticoid Receptor (GR), activating an Androgen Receptor (AR)-independent pathway.

Conclusions:

• APOL3 is a key driver of PCa metastasis and enzalutamide resistance through DAB2IP suppression and GR pathway activation.
• Targeting APOL3 in combination with DAB2IP restoration shows potential for overcoming resistance and halting metastasis in advanced PCa.